CONCORD BIOTECH
|
The Current P/E Ratio of CONCORD BIOTECH is 41.18.
| Share Price | ₹1,218.9 | Feb 25,2026 |
| Market Cap | ₹12,749.2 Cr | |
| Earnings-TTM | ₹309.6 Cr | TTM-Consolidated Results |
| Price/Earnings | 41.18x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of CONCORD BIOTECH
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹12,749.2 Cr] as on Feb 25,2026
(/) Earnings [ ₹309.6 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 41.18x ]
Thus, for CONCORD BIOTECH , the investors are currently willing to pay 41.18 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of CONCORD BIOTECH !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of CONCORD BIOTECH over the last five years.
Historical PE (Price/Earnings) ratio chart of CONCORD BIOTECH
PE Ratio Performance Analysis for CONCORD BIOTECH
- CONCORD BIOTECH 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 19.77x.
- CONCORD BIOTECH 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, CONCORD BIOTECH 's p/e ratio peaked in Mar2024 at 51.68x.
- CONCORD BIOTECH 's p/e ratio hit its five-year low in Mar2023 of 0x.
How does CONCORD BIOTECH 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| CONCORD BIOTECH | 309.61 | 41.18 | 12,749.2 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 38.47 | 423,195.0 |
| DIVIS LABORATORIES LTD | 2,479.00 | 68.52 | 169,849.0 |
| CIPLA LTD | 4,544.70 | 23.92 | 108,703.0 |
| TORRENT PHARMACEUTICALS LTD | 2,272.00 | 65.84 | 149,586.0 |
| DR REDDYS LABORATORIES LTD | 5,508.70 | 19.80 | 109,054.0 |
| MANKIND PHARMA LTD | 1,796.65 | 49.52 | 88,961.6 |
| ZYDUS LIFESCIENCES LTD | 4,933.90 | 18.75 | 92,513.1 |
| LUPIN LTD | 4,669.18 | 22.44 | 104,775.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 20.07 | 70,509.3 |
| ABBOTT INDIA LTD | 1,524.13 | 36.82 | 56,126.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs CONCORD BIOTECH 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.75x |
| Max industry PE | 68.52x |
| Median industry PE | 36.82x |
| Average industry PE | 36.85x |
You may also like the below Video Courses